Dr. Reddy's Laboratories
About: Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Employees: 27,048
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
6,600% more repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 3
222% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $362K
125% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 16
56.92% more ownership
Funds ownership: 14.04% [Q3] → 70.96% (+56.92%) [Q4]
9% more funds holding
Funds holding: 224 [Q3] → 244 (+20) [Q4]
5% more capital invested
Capital invested by funds: $1.79B [Q3] → $1.87B (+$81.9M) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for RDY.
Financial journalist opinion
Based on 3 articles about RDY published over the past 30 days
